St. Jude, iRhythm to co-market cardiac rhythm monitor

St. Jude Medical and iRhythm Technologies have entered into an agreement to market iRhythm’s Zio Patch, a single-use ambulatory cardiac rhythm monitor that recently received FDA 510k clearance.

San Francisco-based iRhythm also closed a $10 million private equity round of financing, led by St. Jude, including investors Mohr Davidow Ventures and Synergy Life Science Partners. The profits of the deal will be used to launch the Zio Patch.

The co-marketing partnership will also include iRhythm’s cardiac rhythm event monitor, the Zio event card, according to St. Paul, Minn.-based St. Jude.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup